[Effective chemotherapy with docetaxel in a patient with breast cancer who had progressed after high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT)].
A 39-year-old female underwent mastectomy for breast cancer in December 1995. However, two years later, she relapsed with multiple bone metastases. Only a partial response was obtained despite tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT). Disease progression with bone pain and an increasing in the level of serum NCC-ST439 occurred 5 months after APBSCT. Salvage chemotherapy with docetaxel 60 mg/m2 reduced her symptoms, and the level of serum NCC-ST439 decreased to within the normal range. Ten cycles of docetaxel administration were repeated without severe adverse reactions in an outpatient setting for 10 months. There is little information regarding treatment after relapse from APBSCT for breast cancer. Docetaxel may be an effective agent for patients in such a setting.
Nishio
M
M
Dept. of Internal Medicine II, Hokkaido University School of Medicine.
Koizumi
K
K
Endo
T
T
Takashima
H
H
Haseyama
Y
Y
Fujimoto
K
K
Yamamoto
S
S
Koike
T
T
Sawada
K
K
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016879:Salvage Therapy; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel